Explainer
Cholesterol explained: LDL, HDL, triglycerides and the 2026 guideline
Cholesterol is a waxy, fat-like substance made by the liver; too much LDL cholesterol builds plaque in arteries and raises the risk of heart attack and stroke.[1][2] In March 2026 a new US guideline brought back LDL targets (below 100, 70 or 55 mg/dL depending on risk) and recommended that every adult have Lp(a) measured once.[3][4]
Cholesterol is one of the most-measured numbers in medicine, and in 2026 the rules for reading it changed.[5] This page explains the basic terms, what the March 2026 US guideline did, and where drugs, Lp(a) and diet fit in. It is the starting point of a short crash course; the other pages are listed under “Course”.
This page is general information, not medical advice. Talk to a clinician about your own cholesterol results and treatment.
What cholesterol is
Cholesterol is a waxy, fat-like substance. Your liver makes it, and your body makes all the blood cholesterol it needs.[1] It travels in the blood inside particles called lipoproteins. Too much of the wrong kind builds up as plaque in artery walls. Plaque narrows the arteries and can block blood flow, causing chest pain (angina) or a heart attack.[6]
High cholesterol has no symptoms, so a blood test is the only way to know your levels.[7] From 2017 to 2020, 86.4 million US adults had high or borderline-high cholesterol.[8]
Cholesterol and triglycerides travel in lipoproteins. LDL particles drive plaque formation, while HDL levels are inversely associated with risk.[2] The causal role of LDL rests largely on randomised trials. A Cholesterol Treatment Trialists’ meta-analysis of 26 statin trials found each 1.0 mmol/L (about 39 mg/dL) fall in LDL cut major vascular events by just over a fifth.[9] It found no threshold below which lowering stopped helping.[10] Raising HDL with drugs has not worked in the same way: the CETP inhibitor torcetrapib raised HDL by 72% but increased deaths.[11]
Apolipoprotein B (apoB) counts atherogenic particles, and the 2026 US guideline says it may be a better risk marker than LDL in some groups, such as people with type 2 diabetes or high triglycerides.[12]
Reading a lipid panel
A standard lipid panel reports LDL (“bad”) cholesterol, HDL (“good”) cholesterol, triglycerides (a blood fat used for energy) and total cholesterol.[2]
| Measure | CDC “optimal” level |
|---|---|
| Total cholesterol | About 150 mg/dL[13] |
| LDL cholesterol | About 100 mg/dL[13] |
| HDL cholesterol | At least 40 mg/dL (men), 50 mg/dL (women)[13] |
| Triglycerides | Below 150 mg/dL[13] |
The CDC says a total cholesterol above 200 mg/dL may be considered high.[14] Most healthy adults should be tested every 4 to 6 years, and some people more often.[15] You may be asked to fast for 8 to 12 hours before the test.[16] Home tests exist too; see the home cholesterol test buyer’s guide.
What the 2026 US guideline changed
On 13 March 2026 the American College of Cardiology, the American Heart Association and nine other groups published a new dyslipidemia guideline that replaces the 2018 cholesterol guideline.[5] The main changes:
- LDL goals are back. The goals are below 100 mg/dL at borderline or intermediate risk, below 70 mg/dL at high risk, and below 55 mg/dL for very-high-risk people with established disease.[3]
- New risk calculator. The PREVENT equations replace the older Pooled Cohort Equations for estimating 10- and 30-year risk.[17]
- Earlier treatment. The guideline recommends considering medication early for young people with familial hypercholesterolemia and for young adults with LDL of 160 mg/dL or more.[18]
- Lp(a) once for everyone. Every adult should have Lp(a) measured at least once.[4] See pcsk9-inhibitors and the Lp(a) explainer.
- More tests when useful. These include coronary artery calcium scans for some people at borderline or intermediate risk, and apoB in selected groups.[12]
In Europe, the ESC and EAS published a focused update of their 2019 dyslipidaemia guidelines in 2025.[19] European and US guidance both recommend testing Lp(a) once in adulthood.[20]
Lowering cholesterol: lifestyle and medicines
CDC prevention advice is to limit saturated fat, eat fibre-rich foods such as oatmeal and beans, keep a healthy weight, stay active, avoid smoking and limit alcohol.[21] Lp(a) is the exception: it is mostly inherited, and lifestyle changes have little effect on it.[22]
statins remain the first-line drug. If they are not enough, the guideline recommends adding ezetimibe, bempedoic acid or a PCSK9 antibody.[23] Newer options arrived in 2026. The FDA approved the first oral PCSK9 inhibitor, enlicitide (Lipfendra), in July.[24] The European Commission approved the CETP inhibitor obicetrapib in September.[25] The CDC reports that only about half of US adults who could benefit from cholesterol medicine take it.[26] The drugs guide compares the options.
Weight-loss drugs also move lipids. In the ATTAIN-1 trial, orforglipron improved triglycerides and non-HDL cholesterol versus placebo;[27] see the GLP-1 crash course. Diet timing is a separate question, covered in the intermittent fasting explainer.
Read next
Cholesterol and fasting research tracker 2026
Live tracker of 2026 lipid and fasting news: the new US guideline, oral PCSK9 approval, obicetrapib in the EU, the pelacarsen miss and fasting trials.
Questions readers ask
What is the difference between LDL and HDL cholesterol?
High LDL cholesterol can lead to plaque buildup in the arteries and heart disease or stroke. High HDL cholesterol is linked to a lower risk of heart disease and stroke, which is why HDL is called "good" cholesterol.[2]
What cholesterol level is considered high?
The CDC says a total cholesterol above 200 mg/dL may be considered high. It lists optimal levels as about 150 mg/dL total, about 100 mg/dL LDL, HDL of at least 40 (men) or 50 (women) mg/dL, and triglycerides below 150 mg/dL.[14][13]
What LDL target does the 2026 US guideline set?
Below 100 mg/dL for people at borderline or intermediate risk, below 70 mg/dL at high risk, and below 55 mg/dL for very-high-risk people with established cardiovascular disease.[3]
How often should cholesterol be checked?
The CDC says most healthy adults should be checked every 4 to 6 years, and people with heart disease, diabetes or a family history of high cholesterol more often.[15]
Do I need to fast before a cholesterol test?
Sometimes. The CDC says you may need to fast for 8 to 12 hours and should ask your doctor how to prepare.[16]
Sources
· 27 claims from 13 publishers
Each numbered claim is a statement we checked against the sources listed with it. Tap a number in the text to see its sources in place.
- [1]
The CDC describes blood cholesterol as a waxy, fat-like substance made by the liver, and says the body makes all the blood cholesterol it needs. confirmedas of 2026-10-11
- About Cholesterol · Centers for Disease Control and Prevention · What it is (retrieved 2026-10-11)
- About Cholesterol · Centers for Disease Control and Prevention · What it is (retrieved 2026-10-11)
- [2]
A standard cholesterol check (lipid panel) measures LDL cholesterol, which can lead to plaque buildup in arteries; HDL cholesterol, high levels of which are linked to lower heart disease and stroke risk; triglycerides, a blood fat used for energy; and total cholesterol. confirmedas of 2026-10-11
- About Cholesterol · Centers for Disease Control and Prevention · What do blood cholesterol numbers mean? (retrieved 2026-10-11)
- About Cholesterol · Centers for Disease Control and Prevention · What do blood cholesterol numbers mean? (retrieved 2026-10-11)
- [3]
The 2026 ACC/AHA guideline brings back LDL cholesterol treatment goals of below 100 mg/dL for people at borderline or intermediate risk, below 70 mg/dL at high risk, and below 55 mg/dL for secondary prevention in people with ASCVD at very high risk. confirmedas of 2026-10-11
- ACC, AHA Release New Clinical Guideline For Managing Dyslipidemia · American College of Cardiology · 2026-03-13 · Treatment Goals Are Back (retrieved 2026-10-11)
- ACC, AHA Release New Clinical Guideline For Managing Dyslipidemia · American College of Cardiology · 2026-03-13 · Treatment Goals Are Back (retrieved 2026-10-11)
- Behind the Guidelines: Top Clinical Takeaways From the 2026 Dyslipidemia Guidelines · HCPLive · 2026-03-23 · Article body (retrieved 2026-10-11)
- [4]
The 2026 ACC/AHA guideline recommends measuring Lp(a) at least once in adulthood (a Class I recommendation), noting that lifestyle changes minimally affect Lp(a) so repeat testing is generally not needed. confirmedas of 2026-10-11
- ACC, AHA Release New Clinical Guideline For Managing Dyslipidemia · American College of Cardiology · 2026-03-13 · Additional Testing (retrieved 2026-10-11)
- Behind the Guidelines: Top Clinical Takeaways From the 2026 Dyslipidemia Guidelines · HCPLive · 2026-03-23 · Article body (retrieved 2026-10-11)
- [5]
On 13 March 2026 the ACC, AHA and nine other organisations published a new US Guideline on the Management of Dyslipidemia in JACC, covering high blood cholesterol, hypertriglyceridemia and elevated Lp(a); it retires and replaces the 2018 cholesterol guideline. confirmedas of 2026-10-11
- ACC, AHA Release New Clinical Guideline For Managing Dyslipidemia · American College of Cardiology · 2026-03-13 · Mar 13, 2026 journal scan (retrieved 2026-10-11)
- 2026 ACC/AHA/AACVPR/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Dyslipidemia (JACC) · Journal of the American College of Cardiology · 2026-03-13 · Abstract, Aim (retrieved 2026-10-11)
- [6]
High blood cholesterol can cause plaque to build up in artery walls, narrowing them and blocking blood flow, which can cause chest pain (angina) or a heart attack. confirmedas of 2026-10-11
- About Cholesterol · Centers for Disease Control and Prevention · What problems does high cholesterol cause? (retrieved 2026-10-11)
- About Cholesterol · Centers for Disease Control and Prevention · What problems does high cholesterol cause? (retrieved 2026-10-11)
- [7]
High cholesterol has no symptoms, so the only way to know your levels is a blood test (a lipid profile). confirmedas of 2026-10-11
- Getting Your Cholesterol Checked · Centers for Disease Control and Prevention · Cholesterol statistics (retrieved 2026-10-11)
- [8]
From 2017 to 2020, 86.4 million US adults aged 20 or older had high or borderline-high cholesterol (total cholesterol of 200 mg/dL or more), according to the CDC. confirmedas of 2026-10-11
- Getting Your Cholesterol Checked · Centers for Disease Control and Prevention · Cholesterol statistics (retrieved 2026-10-11)
- [9]
A Cholesterol Treatment Trialists' meta-analysis of 26 randomised statin trials (about 170,000 participants) found that each 1.0 mmol/L (about 39 mg/dL) reduction in LDL cholesterol cut the annual rate of major vascular events by just over a fifth (rate ratio 0.78) and all-cause mortality by 10%. confirmedas of 2026-10-11
- Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials · The Lancet · 2010-11-13 · Abstract, Interpretation (retrieved 2026-10-11)
- Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials · The Lancet · 2010-11-13 · Abstract, Findings (retrieved 2026-10-11)
- [10]
The 2010 CTT meta-analysis found no evidence of a threshold within the cholesterol range studied and no significant effect on cancer incidence, even at low LDL levels. confirmedas of 2026-10-11
- Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials · The Lancet · 2010-11-13 · Abstract, Interpretation (retrieved 2026-10-11)
- Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials · The Lancet · 2010-11-13 · Abstract, Findings (retrieved 2026-10-11)
- [11]
The earlier CETP inhibitor torcetrapib raised HDL cholesterol by 72.1% but its outcome trial (15,067 patients) was stopped early because it increased cardiovascular events (hazard ratio 1.25) and death from any cause (hazard ratio 1.58). confirmedas of 2026-10-11
- Effects of torcetrapib in patients at high risk for coronary events (ILLUMINATE) · The New England Journal of Medicine · 2007-11-22 · Abstract, Background (retrieved 2026-10-11)
- Effects of torcetrapib in patients at high risk for coronary events (ILLUMINATE) · The New England Journal of Medicine · 2007-11-22 · Abstract, Results (retrieved 2026-10-11)
- [12]
The 2026 guideline recommends selective coronary artery calcium (CAC) scans for men over 40 and women over 45 at borderline or intermediate risk, and says apolipoprotein B may be a more accurate risk marker than LDL cholesterol in groups such as people with type 2 diabetes or high triglycerides. confirmedas of 2026-10-11
- ACC, AHA Release New Clinical Guideline For Managing Dyslipidemia · American College of Cardiology · 2026-03-13 · Additional Testing (retrieved 2026-10-11)
- ACC, AHA Release New Clinical Guideline For Managing Dyslipidemia · American College of Cardiology · 2026-03-13 · Additional Testing (retrieved 2026-10-11)
- [13]
The CDC lists optimal levels as total cholesterol of about 150 mg/dL, LDL cholesterol of about 100 mg/dL, HDL cholesterol of at least 40 mg/dL in men and 50 mg/dL in women, and triglycerides below 150 mg/dL. confirmedas of 2026-10-11
- About Cholesterol · Centers for Disease Control and Prevention · Optimal Cholesterol Levels table (retrieved 2026-10-11)
- About Cholesterol · Centers for Disease Control and Prevention · Optimal Cholesterol Levels table (retrieved 2026-10-11)
- [14]
According to the CDC, a total cholesterol above 200 mg/dL may be considered high in adults and children, a condition also called hyperlipidemia. confirmedas of 2026-10-11
- About Cholesterol · Centers for Disease Control and Prevention · What is high cholesterol? (retrieved 2026-10-11)
- [15]
The CDC says most healthy adults should have their cholesterol checked every 4 to 6 years, and people with heart disease, diabetes or a family history of high cholesterol more often. confirmedas of 2026-10-11
- Getting Your Cholesterol Checked · Centers for Disease Control and Prevention · Who should be tested (retrieved 2026-10-11)
- [16]
The CDC says you may need to fast for 8 to 12 hours before a cholesterol test and should ask your doctor how to prepare. confirmedas of 2026-10-11
- Getting Your Cholesterol Checked · Centers for Disease Control and Prevention · What do I need to know before getting a cholesterol test? (retrieved 2026-10-11)
- [17]
The 2026 guideline recommends the PREVENT-ASCVD equations instead of the older Pooled Cohort Equations for 10- and 30-year risk estimates in adults aged 30 to 79, and says LDL-lowering therapy is reasonable at a borderline 10-year risk of 3% to under 5% and recommended at intermediate risk of 5% to under 10% after a clinician-patient discussion. confirmedas of 2026-10-11
- ACC, AHA Release New Clinical Guideline For Managing Dyslipidemia · American College of Cardiology · 2026-03-13 · Early Intervention and PREVENT Equations (retrieved 2026-10-11)
- ACC, AHA Release New Clinical Guideline For Managing Dyslipidemia · American College of Cardiology · 2026-03-13 · Early Intervention and PREVENT Equations (retrieved 2026-10-11)
- [18]
The 2026 guideline emphasises earlier intervention, recommending early consideration of medication for young people with familial hypercholesterolemia and young adults with LDL cholesterol of 160 mg/dL or more or a strong family history of premature ASCVD. confirmedas of 2026-10-11
- ACC, AHA Release New Clinical Guideline For Managing Dyslipidemia · American College of Cardiology · 2026-03-13 · Early Intervention and PREVENT Equations (retrieved 2026-10-11)
- [19]
The European Society of Cardiology and European Atherosclerosis Society published a 2025 focused update of their 2019 dyslipidaemia guidelines. confirmedas of 2026-10-11
- 2025 Focused Update of the 2019 ESC/EAS Guidelines for the management of dyslipidaemias · European Heart Journal · 2025-11-07 · Title (retrieved 2026-10-11)
- [20]
The European Atherosclerosis Society's 2022 consensus statement recommends testing Lp(a) at least once in adults, and Novartis states that US and European guidelines both recommend once-in-a-lifetime Lp(a) testing for all adults. confirmedas of 2026-10-11
- Lipoprotein(a) in atherosclerotic cardiovascular disease and aortic stenosis: a European Atherosclerosis Society consensus statement · European Heart Journal · 2022-10-14 · Abstract (retrieved 2026-10-11)
- Novartis Lp(a)HORIZON Phase III topline results for pelacarsen (Form 6-K) · Novartis (SEC filing) · 2026-09-04 · About Elevated Lp(a) (retrieved 2026-10-11)
- [21]
CDC prevention advice includes limiting foods high in saturated fat, eating fibre-rich foods such as oatmeal and beans, keeping a healthy weight (overweight and obesity raise LDL), regular physical activity, not smoking and limiting alcohol, which can raise cholesterol and triglycerides. confirmedas of 2026-10-11
- Preventing High Cholesterol · Centers for Disease Control and Prevention · Make healthy eating choices (retrieved 2026-10-11)
- Preventing High Cholesterol · Centers for Disease Control and Prevention · Make healthy eating choices (retrieved 2026-10-11)
- Preventing High Cholesterol · Centers for Disease Control and Prevention · Key points (retrieved 2026-10-11)
- Preventing High Cholesterol · Centers for Disease Control and Prevention · Limit alcohol (retrieved 2026-10-11)
- [22]
Elevated Lp(a) is an inherited risk factor affecting about one in five people worldwide; Lp(a) levels are about 90% genetically determined and largely unaffected by diet or lifestyle, and no targeted Lp(a) treatment was approved as of September 2026. confirmedas of 2026-10-11
- Novartis Lp(a)HORIZON Phase III topline results for pelacarsen (Form 6-K) · Novartis (SEC filing) · 2026-09-04 · About Elevated Lp(a) (retrieved 2026-10-11)
- Ionis partner Novartis announces Lp(a)HORIZON Phase 3 topline results for pelacarsen (Form 8-K exhibit 99.1) · Ionis Pharmaceuticals (SEC filing) · 2026-09-04 · Press release, 4 September 2026 (retrieved 2026-10-11)
- [23]
If lifestyle and statins do not lower LDL cholesterol enough, the 2026 guideline recommends adding nonstatin therapy such as ezetimibe, bempedoic acid or a PCSK9 monoclonal antibody, and notes that inclisiran is still being studied to show whether its LDL lowering reduces cardiac events. confirmedas of 2026-10-11
- ACC, AHA Release New Clinical Guideline For Managing Dyslipidemia · American College of Cardiology · 2026-03-13 · Nonstatin Therapies and Special Considerations (retrieved 2026-10-11)
- ACC, AHA Release New Clinical Guideline For Managing Dyslipidemia · American College of Cardiology · 2026-03-13 · Nonstatin Therapies and Special Considerations (retrieved 2026-10-11)
- [24]
The FDA approved Merck's enlicitide (Lipfendra) 20 mg tablets in July 2026 (FDA action date 15 July; Merck announced it on 16 July) to lower LDL cholesterol in adults with hypercholesterolemia, including heterozygous familial hypercholesterolemia, making it the first FDA-approved oral PCSK9 inhibitor. confirmedas of 2026-10-11
- Merck's LIPFENDRA (enlicitide) is the First and Only Once-Daily Oral PCSK9 Inhibitor Approved by the U.S. FDA to Reduce LDL-C in Adults with Hypercholesterolemia · Merck & Co. (press release via Business Wire) · 2026-07-16 · Press release, 16 July 2026 (retrieved 2026-10-11)
- Drugs@FDA record for LIPFENDRA (NDA 220848), via openFDA · U.S. Food and Drug Administration · submissions, ORIG (retrieved 2026-10-11)
- Merck Announces Second-Quarter 2026 Financial Results (Form 8-K exhibit 99.1) · Merck & Co. (SEC filing) · 2026-08-04 · Pipeline highlights (retrieved 2026-10-11)
- [25]
On 21 September 2026 NewAmsterdam and Menarini announced that the European Commission had granted marketing authorisation for Ubeslo and Evlarco, the first regulatory approval of obicetrapib worldwide, with a requirement to submit final results of the PREVAIL outcomes trial. confirmedas of 2026-10-11
- NewAmsterdam Pharma Form 8-K, European Commission marketing authorization for Ubeslo and Evlarco · NewAmsterdam Pharma (SEC filing) · 2026-09-21 · Item 8.01 (retrieved 2026-10-11)
- NewAmsterdam Pharma Form 8-K, European Commission marketing authorization for Ubeslo and Evlarco · NewAmsterdam Pharma (SEC filing) · 2026-09-21 · Item 8.01 (retrieved 2026-10-11)
- [26]
The CDC reports that slightly more than half of US adults (54.5%, or 47 million people) who could benefit from cholesterol medicine are taking it. confirmedas of 2026-10-11
- High Cholesterol Facts · Centers for Disease Control and Prevention · 2024-10-24 · High total cholesterol in the United States (retrieved 2026-10-11)
- [27]
In the phase 3 ATTAIN-1 trial of 3,127 adults with obesity without diabetes, orforglipron produced mean weight changes of -7.5%, -8.4% and -11.2% at 6, 12 and 36 mg at 72 weeks, versus -2.1% with placebo, with improvements in waist circumference, systolic blood pressure, triglycerides and non-HDL cholesterol. confirmedas of 2025-09-16
- Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment (ATTAIN-1) · The New England Journal of Medicine · 2025-09-16 · Abstract (retrieved 2026-10-10)
- Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment (ATTAIN-1) · The New England Journal of Medicine · 2025-09-16 · Abstract (retrieved 2026-10-10)
- Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment (ATTAIN-1) · The New England Journal of Medicine · 2025-09-16 · Abstract (retrieved 2026-10-10)
Revision history (1)
- Page created.
Created Oct 11, 2026. Last reviewed by an editor on Oct 11, 2026. Next scheduled review: Jan 11, 2027.
Cite this page
"Cholesterol explained: LDL, HDL, triglycerides and the 2026 guideline." ContentLora, updated Oct 11, 2026. https://contentlora.com/explain/cholesterol-explained
Spotted an error? Suggest a correction or emailcorrections@contentlora.com.